About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  Press Releases
  Media Stories
  Download Center
  Video Gallery
  Photo Gallery
  Media Contacts

Biocon: Company Statement Media Reports on USFDA 483s

Bengaluru, Karnataka, India, May 05, 2017:

“With reference to Media Reports on USFDA 483s for Biocon, observations on form 483 is a standard outcome of any audit. Biocon has already responded to USFDA on all observations of the recent audit within stipulated timelines.

As a policy we do not comment on any schedule or outcomes of regulatory inspections, unless we believe that there is a material impact. Biocon has a good track record of inspections by the USFDA, European regulators and other regulators from developed and emerging markets.”

- Company Spokesperson
<< Back


 Download Company  Statement


Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved